Evidence map›Paper›PMID 40329979›Full record

ArticleClinical parkinsonism & related disorders2025

Comparison of clinical measures of motor function with a Holter monitor in Parkinson's disease.

Carlos Pérez-López, Nuria Caballol, Mariateresa Buongiorno, María Asunción Ávila Rivera, Núria López Ariztegui, Lydia López-Manzanares, Jorge Hernández-Vara, Àngels Bayes Rusiñol, Alexandre Gironell Carreró, María Álvarez Saúco and 8 more

Abstract read
In one paragraph

Article in Clinical parkinsonism & related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Carlos Pérez-LópezÀrea de Recerca, Consorci Sanitari de l'Alt Penedès i Garraf, Vilafranca del Pendès, Spain.
Nuria CaballolDepartment of Neurology, Hospital de Sant Joan Despí Moisès Broggi (Barcelona), Spain.
Mariateresa BuongiornoDepartment of Neurology, Hospital Universitari Mútua Terrassa (Barcelona), Spain.
María Asunción Ávila RiveraDepartment of Neurology, Hospital General de l'Hospitalet (Barcelona), Spain.
Núria López ArizteguiDepartment of Neurology, Hospital Universitario de Toledo, Spain.
Lydia López-ManzanaresDepartment of Neurology, Hospital Universitario de la Princesa, Spain.
Jorge Hernández-VaraDepartment of Neurology, Hospital Universitari Vall D'Hebron, Barcelona, Spain.
Àngels Bayes RusiñolParkinson's and Movement Disorders Unit, Hospital Quirón-Teknon, Barcelona, Spain.
Alexandre Gironell CarreróDepartment of Neurology, Hospital de la Santa Creu i Sant Pau (Barcelona), Spain.
María Álvarez SaúcoDepartment of Neurology, Hospital general de Elche (Alicante), Spain.
Elisabet Franquet GomezDepartment of Neurology, Hospital Sant Camil (Barcelona), Spain.
David A Pérez-MartínezNeurology Service, Hospital Universitario 12 de Octubre, Madrid, Spain.
Sonia Escalante ArroyoDepartment of Neurology, Hospital de Tortosa Verge de la Cinta (Tarragona), Spain.
Silvia Martí MartínezDepartment of Neurology, Hospital General de Alicante, Spain.
Pablo MirUnidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
José Mª Salom JuanDepartment of Neurology, Hospital Clínico de Valencia, Spain.
Juan Carlos Martínez-CastrilloMovement Disorders and Neurodegenerative Diseases Unit, IRYCIS, Hospital Ramón y Cajal, Madrid, Spain.
Alejandro Rodríguez-MolineroÀrea de Recerca, Consorci Sanitari de l'Alt Penedès i Garraf, Vilafranca del Pendès, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a significant global health challenge, affecting millions worldwide. This sub-study aims to explore the potential of ambulatory monitoring devices in identifying disease severity and progression in patients. As part of the MOMOPA-EC clinical trial, 156 patients with moderate to severe PD underwent 435 assessments using clinical scales and ambulatory monitoring devices (Parkinson's Holter). This sub-study seeks to establish relations between parameters derived from Holter monitors and clinical severity measures to enhance personalized disease management strategies.

methodsIn the MOMOPA-EC trial, 435 patient monitoring sessions were conducted, during which patients wore Parkinson's Holter monitors for a week before completing clinical assessments, including the Unified Parkinson's Disease Rating Scale (UPDRS), Parkinson's Disease Questionnaire (PDQ-39), and Freezing of Gait Questionnaire (FoG-Q).

resultsThe reports obtained during the monitoring of the patients were classified into three groups based on the greater or lesser gait fluidity (according to the measurements from the Parkinson's Holter). All clinical scales were significantly different in each of these groups, indicating that patients with lower stride fluidity had poorer outcomes across the different clinical scales.

conclusionsThe findings of this study underscore the potential of Parkinson's Holters in providing objective data for personalized disease management in PD patients. Integrating such technologies into routine clinical practice could enhance patient care and treatment strategies by offering clinicians objective insights into both disease progression and therapeutic response.

Indexed as

Automatic ambulatory monitoringMotor fluctuationsParkinson’s diseaseTherapeutic adjustmentWearable sensors

Identifiers

PMID40329979
PMCPMC12051050

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.